Journal of Carcinogenesis
Covering Genesis to Therapeutics

Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 2s, https://carcinogenesis.com/

Infertility as a Multifactorial Health Condition: Current Perspectives on Etiology, Pathophysiology, and Emerging Therapeutic Approaches

Anjali Sharma[1], Shailendra Sharma[2], Shivam Agarwal[*3], Baijnath Das[4], Ankit Singh[5], Prerna Rajput[6], Shivmohan Singh[7]

[1]Assistant Professor, Department of Medical Laboratory Technology, Chandigarh University,

Email ID: a67488381@gmail.com

[2]HOD (Professor), Department- Medical Laboratory Sciences, Vivek University Bijnor U.P. India,

Email ID; Shailendrapatho@gmail.com

[*3]Assistant Professor, Teerthanker Mahaveer University College of Paramedical Sciences, TMU, Moradabad, Uttar Pradesh, India-244001. (ORCID ID: 0000-0002-7891-9389) Email ID: shivamagarwal50283@gmail.com

[4]Lecturer, Teerthanker Mahaveer University College of Paramedical Sciences, TMU, Moradabad, Uttar Pradesh, India-244001. Email ID: baijnathdasbiochemaiims@gmail.com

[5]Research Scholar, (M.Sc. MLT in Microbiology), Vivekanand Global University Jaipur,

Email ID; ankitjaat7248@gmail.com

[6]Associate Professor, Department of Medical Laboratory Science, Vivek University Bijnor U.P. India,

Email ID; prernarajput343@gmail.com

[7]Assistant Professor, Institute of Paramedical Sciences, Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India-201312. Email ID: shivbais.thakur10@gmail.com / ORCID ID: 0009000143442218

***Corresponding Author:**

Shivam Agarwal

Email ID: shivamagarwal50283@gmail.com

ABSTRACT

Infertility, a complex and multifactorial health condition, affects a significant proportion of the global population, with profound physiological and psychosocial implications. It is defined as the inability to achieve pregnancy after 12 months or more of regular, unprotected sexual intercourse. The etiology of infertility is diverse, encompassing endocrine disorders, genetic abnormalities, infections, anatomical defects, and environmental or lifestyle factors. In males, common causes include varicocele, hormonal imbalances, and impaired spermatogenesis, while in females, ovulatory dysfunction, tubal obstruction, endometriosis, and polycystic ovary syndrome are predominant contributors. The pathophysiology of infertility reflects disruptions in normal reproductive physiology, often driven by oxidative stress, hormonal dysregulation, or immune-mediated damage. Diagnostic approaches have advanced, incorporating hormonal assays, imaging techniques, semen analysis, and laparoscopy to identify underlying causes in both sexes. The impact of infertility extends beyond reproductive challenges, significantly affecting physical health, emotional well-being, and social relationships. Preventive and therapeutic strategies include pharmaceutical interventions—such as ovulation induction agents, gonadotropins, and emerging assisted reproductive technology approaches—and non-pharmaceutical measures, including lifestyle modifications, nutritional support, and stress reduction. A multidisciplinary approach is essential for effective management. This review synthesizes current insights into infertility's etiology, pathophysiology, diagnostic pathways, health consequences, and therapeutic strategies, emphasizing the need for individualized, evidence-based care.

Keywords: *Infertility, Reproductive Health, Mental Health, Pharmaceutical Interventions, Non-Pharmaceutical Measures, Assisted Reproductive Technology.*

How to Cite: Anjali Sharma, Shailendra Sharma, Shivam Agarwal, Baijnath Das, Ankit Singh, Prerna Rajput, Shivmohan Singh, (2025) Infertility as a Multifactorial Health Condition: Current Perspectives on Etiology, Pathophysiology, and Emerging Therapeutic Approaches, *Journal of Carcinogenesis*, *Vol.24, No.2s*, 437-445

1. INTRODUCTION

Infertility, defined as the inability to conceive after one year or more of regular, unprotected intercourse, is a significant global health concern affecting both men and women (1). It impacts millions worldwide, with a substantial proportion of individuals experiencing infertility during their reproductive years (2). This prevalence spans economic divides, affecting both high-income and low- to middle-income regions (3). Infertility manifests in two primary forms: primary, where no prior pregnancy has occurred, and secondary, where previous conception was achieved but subsequent attempts are unsuccessful (4). These forms arise from a complex interplay of biological, environmental, lifestyle, and healthcare access factors (5). Recent trends indicate a rise in secondary infertility, driven by delayed parenthood, urban lifestyles, and reproductive health challenges (6). For example, in some regions, primary infertility affects a significant proportion of women of reproductive age, with male factors contributing substantially to overall cases (7). In certain countries, infertility rates have risen over recent decades, fueled by declining fertility rates and aging populations (8). The psychological and social consequences are profound, particularly in regions where cultural emphasis on fertility leads to stigma, marital strain, and social exclusion for infertile individuals (9). Global health crises have further amplified emotional distress for those navigating infertility, underscoring the urgent need for accessible reproductive care (10). Physiologically, successful reproduction relies on precise hormonal regulation via the hypothalamic–pituitary–gonadal axis (11). In women, gonadotropin-releasing hormone stimulates follicle-stimulating hormone and luteinizing hormone, driving ovarian follicle development and ovulation (12). In men, disruptions in testicular function, sperm transport, or hormonal balance—due to congenital conditions or lifestyle factors—can lead to subfertility or infertility (13). Common contributors include impaired sperm motility, testicular abnormalities, and hormonal imbalances (14). Access to infertility treatments remains uneven, particularly in low- and middle-income regions. Assisted Reproductive Technologies (ART), while effective, are often prohibitively expensive, imposing significant financial burdens (15). Even in high-income countries, the growing demand for ART strains healthcare systems. Limited insurance coverage and high out-of-pocket costs exacerbate economic challenges, often impacting productivity for affected individuals (16). Extensive research over recent decades has provided critical insights into infertility trends (17). Recent analyses encompass both male and female infertility, enabling regional comparisons and disease burden projections (18). Unlike chronic conditions, infertility is highly responsive to short-term interventions, requiring shorter forecast periods to reflect the rapid impact of medical and policy measures (19). This review examines the etiology, pathophysiological mechanisms, diagnostic advancements, and therapeutic strategies for infertility from a comprehensive, gender-inclusive perspective, ensuring ethical considerations are upheld.

2. ETIOLOGY

Infertility is a multifactorial condition, with causes broadly categorized into issues related to ovulation, gamete or embryo transport, and implantation (20).

Male infertility results from disruptions in spermatogenesis, sperm transport, delivery, or external factors (see Table 1) (14).

Table 1: Etiological Factors of Male Infertility

Category	Cause	Description
Defective Spermatogenesis	Hormonal Disorders	Diabetes, hyperthyroidism disrupt HPT axis, causing azoospermia/non-viable sperm.
	Testicular Abnormalities	Cryptorchidism, varicocele, scrotal heat impairs sperm production/quality.
	Genetic Causes	Klinefelter syndrome, Y-chromosome microdeletions compromise spermatogenesis.
	Sperm Morphology/Motility	Structural defects, immotility, DNA fragmentation prevent fertilization.
Defective Sperm Transport	Ductal Obstructions	Congenital absence, infections, vasectomy block vas deferens/seminal vesicles.
	Infections	STIs (e.g., chlamydia, gonorrhea) cause scarring, impairing sperm transit.
Ineffective Sperm Delivery	Structural/Functional Disorders	Erectile dysfunction, ejaculatory issues, hypospadias hinder sperm deposition.

External Influences	Lifestyle Factors	Alcohol, smoking, cannabis, cocaine impairs spermatogenesis/hormonal balance.
	Environmental Toxins	Heavy metals (e.g., lead), pesticides, heat reduce sperm quantity/viability.
	Immunological Factors	Antisperm antibodies (post-infection/trauma) impair sperm function.

Female infertility arises from defective ovulation, impaired gamete or embryo transport, or implantation issues (see Table 2) (21).

Table 2: Etiological Factors of Female Infertility

Category	Cause	Description
Defective Ovulation	Endocrine Disorders	Hyperprolactinemia, thyroid/adrenal issues inhibit gonadotropin secretion/ovulation.
	Lifestyle/Physical Disorders	Obesity, anorexia, excessive exercise causes hormonal imbalances, anovulation.
	Polycystic Ovary Syndrome (PCOS)	Hyperandrogenism, high LH, insulin resistance disrupts follicular maturation.
	Endometriosis	Ectopic endometrial tissue causes inflammation, cysts, adhesions, blocking ovulation.
	Gonadotropin Deficiency	Low GnRH, FSH, LH halt estrogen/progesterone synthesis, causing anovulation.
	Anovulatory Triggers	Stress, high/low BMI, poor nutrition, excessive exercise suppress HPO axis.
Defective Transport	Fallopian Tube Obstruction	PID, STIs (e.g., chlamydia, gonorrhea), tubal surgeries cause blockages.
	Post-Surgical Adhesions	Scar tissue from surgeries distorts uterus/ovaries/tubes, impairing transport.
	Sperm Transport Barriers	Vaginismus, dyspareunia, cervical infections, antisperm antibodies block sperm.
Impaired Implantation	Congenital Anomalies/Fibroids	Bicornuate uterus, fibroids near cervix/tubes disrupt embryo implantation.
	Endometrial Deficiency	Damaged/inflamed endometrium (from drugs/infections) hinders embryo adherence.
	Ectopic Pregnancy History	Prior tubal pregnancies indicate tubal dysfunction, increasing infertility risk.
	Infections	Chronic bacterial/viral/fungal infections cause endometrial scarring/inflammation.
	Immunological Factors	Antisperm/anti-embryo antibodies disrupt implantation, cause pregnancy loss.
External Influences	Environmental/Lifestyle Factors	Tobacco, alcohol, cannabis, endocrine disruptors impair ovulation/receptivity.
	Age/Nutritional Extremes	Age >35 reduces ovarian reserve; malnutrition/obesity disrupts hormonal balance.

3. PATHOPHYSIOLOGY

Infertility, a complex and multifactorial condition, arises from disruptions in the physiological processes essential for successful reproduction (22). In males, infertility is often related to abnormalities in spermatogenesis, sperm transport, or hormonal regulation (23). Disruptions in the hypothalamic–pituitary–gonadal (HPG) axis can impair the secretion of gonadotropins—luteinizing hormone (LH) and follicle-stimulating hormone (FSH)—which are critical for testosterone production and spermatogenesis (11). Testicular factors, such as varicocele, cryptorchidism, testicular trauma, or infections like orchitis, can impair Sertoli and Leydig cell function, reducing sperm quality and count (24). Additionally, genetic mutations, oxidative stress, and exposure to environmental toxins or endocrine-disrupting chemicals can damage sperm DNA and impair motility, contributing to subfertility or infertility (25).

In females, infertility typically results from dysfunction in ovulation, tubal patency, or endometrial receptivity (26).

Hormonal imbalances, particularly in polycystic ovary syndrome (PCOS), disrupt regular oocyte release due to altered gonadotropin and insulin signaling (27). Disorders of the HPG axis, such as hypothalamic amenorrhea or premature ovarian insufficiency, can lead to anovulation (28). Tubal factor infertility, often caused by pelvic inflammatory disease (PID) or endometriosis, impairs the transport of the oocyte or zygote (29). Endometrial abnormalities, such as uterine fibroids or a thin endometrium, hinder implantation (30). Furthermore, oxidative stress, autoimmunity, and chromosomal anomalies may exacerbate female infertility (31). The complex interplay of endocrine, structural, and environmental factors underscores the multifaceted nature of infertility pathophysiology in both sexes (32).

4. IMPACT OF INFERTILITY ON HEALTH

Infertility is not merely a reproductive issue; it exerts a profound impact on an individual's physical, psychological, and social well-being (33). Physically, infertility may indicate underlying health conditions, such as PCOS, endometriosis, thyroid dysfunction, diabetes, varicocele, or infections like STDs, all of which can compromise reproductive capacity (34). These conditions often persist beyond fertility concerns, contributing to chronic metabolic, hormonal, or inflammatory disorders (35). Hormonal imbalances associated with infertility can also disrupt secondary physiological functions, leading to fatigue, weight fluctuations, and sexual dysfunction (34).

Psychologically, infertility is frequently linked to emotional distress (36). Individuals experiencing infertility often report heightened levels of anxiety, depression, irritability, and diminished self-worth (37). The inability to conceive may be perceived as a personal failure, particularly in cultures where parenthood is central to adult identity (36). This emotional burden is intensified by the uncertainty and invasiveness of diagnostic procedures and assisted reproductive treatments, which may involve repeated cycles of hope and failure, creating a significant psychological toll (38). For couples, this strain can disrupt communication, intimacy, and overall relationship satisfaction (39).

Socially, the stigma associated with infertility can lead to isolation, discrimination, and strained family dynamics (40). In some societies, individuals—particularly women—may face social exclusion, blame, or pressure to pursue alternative reproductive options, such as remarriage or surrogacy (41). Financially, infertility treatments, including in vitro fertilization (IVF), intrauterine insemination (IUI), and hormone therapies, are often prohibitively expensive and not covered by health insurance, imposing significant economic burdens on affected individuals and families (42).

5. DIAGNOSIS OF INFERTILITY

The diagnostic evaluation of infertility requires a structured approach for both sexes (43). Flowchart 1 outlines the assessment of male infertility, beginning with a clinical history and physical examination, followed by semen analysis as the primary test (44). Abnormal findings may prompt hormonal assays (e.g., FSH, LH, testosterone), genetic testing (e.g., karyotyping, Y-chromosome microdeletion analysis), or imaging studies, such as scrotal ultrasound or transrectal ultrasound, to evaluate suspected obstructions (45).



Flowchart 1 illustrates the diagnostic approach to male infertility, starting with clinical evaluation and semen analysis, followed by targeted hormonal, genetic, and imaging studies based on initial findings.

The female infertility testing starts with a menstrual history and ovulatory assessment (46)using hormonal profiles (e.g., FSH, LH, AMH, prolactin, TSH) and ovulation tracking (2). Pelvic ultrasound evaluates reproductive anatomy, while tubal patency is assessed through hysterosalpingography (HSG) (47). Advanced imaging or laparoscopy may be indicated for suspected endometriosis or unexplained infertility (48). The diagnosis of female infertility illustrates in Flowchart 2.



Flowchart 2 outlines the diagnostic pathway for female infertility, encompassing clinical history, ovulatory assessment, pelvic and tubal evaluation, and cervical factor analysis to identify underlying causes.

6. PHARMACOLOGICAL APPROACHES

One of the primary pharmacological strategies for treating female infertility involves ovulation induction (49). Clomiphene citrate (Clomid), a selective estrogen receptor modulator (SERM), is a first-line treatment that blocks estrogen receptors in the hypothalamus to stimulate increased release of FSH and LH (50). Letrozole (Femara), an aromatase inhibitor, has gained prominence, particularly for women with PCOS, as it reduces estrogen production, thereby promoting gonadotropin secretion (51). Recombinant FSH (r-FSH; e.g., Gonal-F, follitropin alfa) and human menopausal gonadotropins (hMG; e.g., Menopur) are used when oral agents fail, particularly in ART such as IVF (52), these agents stimulate follicular development directly at the ovarian level (12).

Hyperprolactinemia-related infertility is treated with dopamine agonists, such as bromocriptine and cabergoline, which inhibit prolactin secretion and restore ovulatory function (53). Cabergoline is preferred due to its longer half-life and better tolerability (54). For luteal phase insufficiency, micronized progesterone (e.g., Utrogestan) or progesterone gel (e.g., Crinone) is administered during the luteal phase or post-embryo transfer to enhance endometrial receptivity (55).

For patients with PCOS, metformin, an insulin sensitizer, is widely used to address hyperinsulinemia, restore ovulation, and reduce androgen levels (56). Combination therapy with letrozole and metformin has shown improved ovulation and pregnancy rates compared to monotherapy (57). Recently, inositol (myo-inositol and D-chiro-inositol) has been studied as a supplement to enhance insulin sensitivity and ovarian function in PCOS (58).

In men with hypogonadotropic hypogonadism, human chorionic gonadotropin (hCG) and recombinant FSH (r-FSH) are administered to stimulate testosterone production and spermatogenesis (59). For idiopathic oligospermia, empirical treatments, such as clomiphene citrate or tamoxifen, are used to stimulate endogenous gonadotropin release (60). Additionally, antioxidant supplementation—including coenzyme Q10, L-carnitine, vitamin E, zinc, and selenium—is commonly employed to reduce oxidative stress and improve sperm quality (61). Emerging pharmacological options under investigation include aromatase inhibitors (e.g., anastrozole) for men with elevated estradiol levels and low testosterone (62).

In ART procedures, such as IVF, controlled ovarian hyperstimulation is achieved using gonadotropin-releasing hormone (GnRH) agonists (e.g., leuprolide) or GnRH antagonists (e.g., cetrorelix, ganirelix) to prevent premature LH surges (63). Ovulation is triggered with hCG (e.g., Ovitrelle) or recombinant LH, and luteal support is provided using progesterone vaginal gels, oral micronized progesterone, or intramuscular injections (64). Recent advancements include recombinant LH and FSH combinations and long-acting formulations, such as corifollitropin alfa (Elonva), which reduce injection frequency and improve patient compliance (65).

7. NON-PHARMACEUTICAL MEASURES IN THE PREVENTION AND MANAGEMENT OF INFERTILITY

Non-pharmaceutical approaches are a cornerstone in the holistic prevention and management of infertility, complementing pharmacological therapies (66). Lifestyle interventions are highly impactful, particularly in cases of idiopathic infertility or where modifiable risk factors are present (67). Maintaining optimal body weight through regular physical activity and a nutritionally balanced diet—rich in micronutrients, antioxidants, and healthy fats (68)—positively affects both spermatogenesis and ovulatory function (69). Several studies indicate that lifestyle-induced oxidative stress contributes significantly to gamete dysfunction, making lifestyle changes aimed at reducing oxidative load beneficial (70).

Stress reduction through psychological support, cognitive behavioral therapy, yoga, or meditation is increasingly recognized, given the bidirectional relationship between stress and reproductive hormones (71). Reducing exposure to endocrine-disrupting chemicals (EDCs), such as phthalates, bisphenol A (BPA), and certain pesticides, is essential, as these agents impair hormonal balance and gamete quality (72). Avoidance of tobacco, excessive alcohol, and recreational drugs is critical, as these substances disrupt the hypothalamic–pituitary–gonadal axis, contributing to reduced fertility (73). Timely screening and treatment of sexually transmitted infections, particularly *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, are vital to prevent tubal and testicular damage (74). Finally, public health initiatives promoting reproductive education, preconception care, and early fertility assessment can facilitate early identification of at-risk individuals and enable timely interventions, ultimately improving reproductive outcomes (75).

8. CONCLUSION

Infertility is a multifaceted and growing global health issue that encompasses biological, psychological, and social dimensions. The complexity of its etiology—ranging from hormonal imbalances, genetic mutations, and anatomical anomalies to lifestyle and environmental factors—demands a multidisciplinary approach to diagnosis and management. Advances in diagnostic tools and pharmaceutical interventions, including ovulation induction agents, ART protocols, and hormone therapies, have significantly enhanced reproductive outcomes for many individuals. Simultaneously, non-pharmaceutical measures such as lifestyle modification, stress management, and environmental awareness have emerged as essential components of preventive care and supportive therapy. Importantly, the psychological burden of infertility, including emotional distress, stigma, and strained relationships, underscores the need for holistic and compassionate care models that integrate mental health support. Equitable access to diagnostic and treatment services remains a global challenge, particularly in resource-limited settings. As research continues to uncover novel therapeutic targets and refine ART technologies, a patient-centered, evidence-based, and ethically grounded approach is critical for improving fertility outcomes and enhancing overall well-being. Addressing infertility requires not only clinical intervention but also broader public health strategies, policy support, and social awareness to reduce stigma and ensure reproductive rights for all.

REFERENCES

[1] Carson SA, Kallen AN. Diagnosis and Management of Infertility: A Review. JAMA. 2021 Jul 6;326(1):65–76.

[2] Bonavina G, Taylor HS. Endometriosis-associated infertility: From pathophysiology to tailored treatment. Front Endocrinol (Lausanne). 2022;13:1020827.

[3] Coates MM, Ezzati M, Robles Aguilar G, Kwan GF, Vigo D, Mocumbi AO, et al. Burden of disease among the world's poorest billion people: An expert-informed secondary analysis of Global Burden of Disease estimates. PLoS One. 2021 Aug 16;16(8):e0253073.

[4] Organization WH. WHO fact sheet on infertility. Global Reproductive Health. 2021 Spring;6(1):e52.

[5] Phillips K, Olanrewaju RA, Omole F. Infertility: Evaluation and Management. Am Fam Physician. 2023 Jun;107(6):623–30.

[6] Pados G, Gordts S, Sorrentino F, Nisolle M, Nappi L, Daniilidis A. Adenomyosis and Infertility: A Literature Review. Medicina (Kaunas). 2023 Aug 26;59(9):1551.

[7] Karunyam BV, Abdul Karim AK, Naina Mohamed I, Ugusman A, Mohamed WMY, Faizal AM, et al. Infertility and cortisol: a systematic review. Front Endocrinol (Lausanne). 2023;14:1147306.

[8] Wyrwoll MJ, van der Heijden GW, Krausz C, Aston KI, Kliesch S, McLachlan R, et al. Improved phenotypic classification of male infertility to promote discovery of genetic causes. Nat Rev Urol. 2024 Feb;21(2):91–101.

[9] Mazzilli R, Rucci C, Vaiarelli A, Cimadomo D, Ubaldi FM, Foresta C, et al. Male factor infertility and assisted reproductive technologies: indications, minimum access criteria and outcomes. J Endocrinol Invest. 2023 Jun;46(6):1079–85.

[10] Magomedova A, Fatima G. Mental Health and Well-Being in the Modern Era: A Comprehensive Review of Challenges and Interventions. Cureus. 17(1):e77683.

[11] Acevedo-Rodriguez A, Kauffman AS, Cherrington BD, Borges CS, Roepke TA, Laconi M. Emerging insights into Hypothalamic-pituitary-gonadal (HPG) axis regulation and interaction with stress signaling. J Neuroendocrinol. 2018 Oct;30(10):e12590.

[12] Orlowski M, Sarao MS. Physiology, Follicle Stimulating Hormone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Aug 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK535442/

[13] Sharma A, Minhas S, Dhillo WS, Jayasena CN. Male infertility due to testicular disorders. J Clin Endocrinol Metab. 2020 Dec 9;106(2):e442–59.

[14] Babakhanzadeh E, Nazari M, Ghasemifar S, Khodadadian A. Some of the Factors Involved in Male Infertility: A Prospective Review. Int J Gen Med. 2020 Feb 5;13:29–41.

[15] Kashyap S, Tripathi P. Assisted Reproductive Technology (Regulation) Act 2021: Critique and Contestations. Asian Bioeth Rev. 2023 Jul 11;16(2):149–64.

[16] Dhankhar A, Kumari R, Bahurupi YA. Out-of-Pocket, Catastrophic Health Expenditure and Distress Financing on Non-Communicable Diseases in India: A Systematic Review with Meta-Analysis. Asian Pac J Cancer Prev. 2021 Mar;22(3):671–80.

[17] Huo M, Wang Y, Yuan X, Yuan Y, Zhang X. Changing trends in the global burden of polycystic ovarian syndrome-related infertility over the past 30 years: retrospective data analysis of the global burden of disease study 2019. BMC Women's Health. 2025 Jan 23;25(1):35.

[18] Liu J, Qin Y, Liu H, Liu Y, Yang Y, Ning Y, et al. Global, regional, and national burden of female infertility and trends from 1990 to 2021 with projections to 2050 based on the GBD 2021 analysis. Sci Rep. 2025 May 21;15:17559.

[19] Feng J, Wu Q, Liang Y, Liang Y, Bin Q. Epidemiological characteristics of infertility, 1990–2021, and 15-year forecasts: an analysis based on the global burden of disease study 2021. Reprod Health. 2025 Feb 19;22:26.

[20] Deshpande PS, Gupta AS. Causes and Prevalence of Factors Causing Infertility in a Public Health Facility. J Hum Reprod Sci. 2019;12(4):287–93.

[21] Walker MH, Tobler KJ. Female Infertility. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Aug 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK556033/

[22] Saftić Martinović L, Mladenić T, Lovrić D, Ostojić S, Dević Pavlić S. Decoding the Epigenetics of Infertility: Mechanisms, Environmental Influences, and Therapeutic Strategies. Epigenomes. 2024 Sep 5;8(3):34.

[23] Leslie SW, Soon-Sutton TL, Khan MA. Male Infertility. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Aug 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK562258/

[24] Cargnelutti F, Di Nisio A, Pallotti F, Spaziani M, Tarsitano MG, Paoli D, et al. Risk factors on testicular function in adolescents. J Endocrinol Invest. 2022;45(9):1625–39.

[25] Kharrazian D. Exposure to Environmental Toxins and Autoimmune Conditions. Integr Med (Encinitas). 2021 Apr;20(2):20–4.

[26] Carson SA, Kallen AN. Diagnosis and Management of Infertility. JAMA. 2021 Jul 6;326(1):65–76.

[27] Emanuel RHK, Roberts J, Docherty PD, Lunt H, Campbell RE, Möller K. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Front Endocrinol (Lausanne). 2022 Nov 15;13:1017468.

[28] Mikhael S, Punjala-Patel A, Gavrilova-Jordan L. Hypothalamic-Pituitary-Ovarian Axis Disorders Impacting Female Fertility. Biomedicines. 2019 Jan 4;7(1):5.

[29] Price MJ, Ades AE, Soldan K, Welton NJ, Macleod J, Simms I, et al. Pelvic inflammatory disease and tubal factor infertility. In: The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis [Internet]. NIHR Journals Library; 2016 [cited 2025 Aug 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK350656/

[30] Navarro A, Bariani MV, Yang Q, Al-Hendy A. Understanding the Impact of Uterine Fibroids on Human Endometrium Function. Front Cell Dev Biol. 2021 May 25;9:633180.

[31] Souliotis VL, Vlachogiannis NI, Pappa M, Argyriou A, Ntouros PA, Sfikakis PP. DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. Int J Mol Sci. 2019 Dec 20;21(1):55.

[32] Makwe CC, Ugwu AO, Sunmonu OH, Yusuf-Awesu SA, Ani-Ugwu NK, Olumakinwa OE. Hysterosalpingography findings of female partners of infertile couple attending fertility clinic at Lagos

University Teaching Hospital. Pan Afr Med J. 2021;40:223.

[33] Assaysh-Öberg S, Borneskog C, Ternström E. Women's experience of infertility & treatment – A silent grief and failed care and support. Sexual & Reproductive Healthcare. 2023 Sep 1;37:100879.

[34] Vannuccini S, Clifton VL, Fraser IS, Taylor HS, Critchley H, Giudice LC, et al. Infertility and reproductive disorders: impact of hormonal and inflammatory mechanisms on pregnancy outcome. Hum Reprod Update. 2016;22(1):104–15.

[35] Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril. 2018 Oct;110(5):794–809.

[36] Sharma A, Shrivastava D. Psychological Problems Related to Infertility. Cureus. 14(10):e30320.

[37] Rooney KL, Domar AD. The relationship between stress and infertility. Dialogues Clin Neurosci. 2018 Mar;20(1):41–7.

[38] Kienzler H, Massazza A, Kuykendall R, Tamimi N, Hammoudeh W, Giacaman R. Uncertainty and mental health: A qualitative scoping review. SSM - Qualitative Research in Health. 2025 Jun 1;7:100521.

[39] The Hidden Toll: Understanding The Impact Of Anxiety And Depression On Relationships | The Sterling Institute [Internet]. 2025 [cited 2025 Aug 2]. Available from: https://sterlinginstitute.org/relationships-anxiety-depression/

[40] Taebi M, Kariman N, Montazeri Ph.D.4 A, Majd HA. Infertility Stigma: A Qualitative Study on Feelings and Experiences of Infertile Women. Int J Fertil Steril. 2021;15(3):189–96.

[41] Fiorilli C, Barni D, Endendijk J, Retelsdorf J. Editorial: Gender differences and disparities in socialization contexts: How do they matter for healthy relationships, wellbeing, and achievement-related outcomes? Front Psychol. 2022 Dec 2;13:1103425.

[42] Njagi P, Groot W, Arsenijevic J, Dyer S, Mburu G, Kiarie J. Financial costs of assisted reproductive technology for patients in low- and middle-income countries: a systematic review. Hum Reprod Open. 2023 Mar 1;2023(2):hoad007.

[43] Diagnostic evaluation of the infertile female: a committee opinion - PubMed [Internet]. [cited 2025 Aug 2]. Available from: https://pubmed.ncbi.nlm.nih.gov/25936238/

[44] Fraga LG, Gismondi JPM, Sanvido LV, Lozano AFQ, Teixeira TA, Hallak J. Clinical and Laboratorial Evaluation of Male Infertility. A Detailed Practical Approach. Archives of Medical Research. 2024 Dec 1;55(8):103139.

[45] Amorosa LF. Abbreviated Tests of Endocrine Function. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations [Internet]. 3rd ed. Boston: Butterworths; 1990 [cited 2025 Aug 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK704/

[46] Yang AM, Cui N, Sun YF, Hao GM. Letrozole for Female Infertility. Front Endocrinol (Lausanne). 2021;12:676133.

[47] Panchal S, Nagori C. Imaging techniques for assessment of tubal status. J Hum Reprod Sci. 2014;7(1):2–12.

[48] Mak J, Leonardi M, Condous G. 'Seeing is believing': arguing for diagnostic laparoscopy as a diagnostic test for endometriosis. Reprod Fertil. 2022 Jun 10;3(3):C23–8.

[49] Sharma M, Balasundaram P. Ovulation Induction Techniques. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Aug 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK574564/

[50] Feh MKM, Patel P, Wadhwa R. Clomiphene. In: StatPearls [Internet] [Internet]. StatPearls Publishing; 2024 [cited 2025 Aug 2]. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK559292/

[51] Guang H juan, Li F, Shi J. Letrozole for patients with polycystic ovary syndrome. Medicine (Baltimore). 2018 Nov 2;97(44):e13038.

[52] Bergandi L, Canosa S, Carosso AR, Paschero C, Gennarelli G, Silvagno F, et al. Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization. Pharmaceuticals (Basel). 2020 Jun 27;13(7):136.

[53] Kaiser UB. Hyperprolactinemia and infertility: new insights. J Clin Invest. 2012 Oct 1;122(10):3467–8.

[54] Otis A, Brochet M, Tremblay Z, Balayla J, Dahdouh EM. Cabergoline Use and Pregnancy Outcomes: A Systematic Review. Birth Defects Res. 2025 Mar;117(3):e2464.

[55] Malik S, Krishnaprasad K. Natural Micronized Progesterone Sustained Release (SR) and Luteal Phase: Role Redefined!! J Clin Diagn Res. 2016 Feb;10(2):QE01–4.

[56] Lauretta R, Lanzolla G, Vici P, Mariani L, Moretti C, Appetecchia M. Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. Int J Endocrinol. 2016;2016:8671762.

[57] Fatima N, Ellahi A. Outcome of Metformin-Letrozole Therapy In Patients With Metformin-Clomiphene Resistant Polycystic Ovarian Syndrome. Journal of Surgery Pakistan. 2019;

[58] Lete I, Martínez A, Lasaga I, Centurión E, Vesga A. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecol Endocrinol. 2024 Dec;40(1):2301554.

[59] Boeri L, Capogrosso P, Salonia A. Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism. Curr Pharm Des. 2021;27(24):2775–83.

[60] Dabaja AA, Schlegel PN. Medical treatment of male infertility. Transl Androl Urol. 2014 Mar;3(1):9–16.

[61] Tippairote T, Bjørklund G, Gasmi A, Semenova Y, Peana M, Chirumbolo S, et al. Combined Supplementation of Coenzyme Q10 and Other Nutrients in Specific Medical Conditions. Nutrients. 2022 Oct 19;14(20):4383.

[62] Amaral C, Almeida CF, Valente MJ, Varela CL, Costa SC, Roleira FMF, et al. New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment. Cancers (Basel). 2025 Jan 7;17(2):165.

[63] Jain M, Singh M. Assisted Reproductive Technology (ART) Techniques. In: StatPearls [Internet] [Internet]. StatPearls Publishing; 2023 [cited 2025 Aug 2]. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK576409/

[64] Dashti S, Eftekhar M. Luteal-phase support in assisted reproductive technology: An ongoing challenge. Int J Reprod Biomed. 2021 Oct 10;19(9):761–72.

[65] Bielfeld AP, Schwarze JE, Verpillat P, Lispi M, Fischer R, Hayward B, et al. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years. Reprod Biomed Online. 2024 Jun;48(6):103725.

[66] Castellano-Tejedor C. Non-Pharmacological Interventions for the Management of Chronic Health Conditions and Non-Communicable Diseases. Int J Environ Res Public Health. 2022 Jul 13;19(14):8536.

[67] Jeon B, Kang T, Choi SW. Lifestyle factors and health outcomes associated with infertility in women: A case-control study using National Health Insurance Database. Reproductive Health. 2025 May 21;22(1):88.

[68] Rippe JM. Lifestyle Medicine: The Health Promoting Power of Daily Habits and Practices. Am J Lifestyle Med. 2018 Jul 20;12(6):499–512.

[69] Chao HH, Zhang Y, Dong PY, Gurunathan S, Zhang XF. Comprehensive review on the positive and negative effects of various important regulators on male spermatogenesis and fertility. Front Nutr. 2023 Jan 16;9:1063510.

[70] Sharifi-Rad M, Anil Kumar NV, Zucca P, Varoni EM, Dini L, Panzarini E, et al. Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases. Front Physiol. 2020 Jul 2;11:694.

[71] Simon NM, Hofmann SG, Rosenfield D, Hoeppner SS, Hoge EA, Bui E, et al. Efficacy of Yoga vs Cognitive Behavioral Therapy vs Stress Education for the Treatment of Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021 Jan 1;78(1):13–20.

[72] Park J, Lee H, Lee S, Lee H. Interventions on Reducing Exposure to Endocrine Disrupting Chemicals in Human Health Care Context: A Scoping Review. Risk Manag Healthc Policy. 2022 Apr 26;15:779–91.

[73] Tuhin M. Smoking, Alcohol & Drugs: The Medical Risks [Internet]. Science News Today. 2025 [cited 2025 Aug 2]. Available from: https://www.sciencenewstoday.org/smoking-alcohol-drugs-the-medical-risks

[74] Keegan MB, Diedrich JT, Peipert JF. Chlamydia trachomatis Infection: Screening and Management. J Clin Outcomes Manag. 2014 Jan;21(1):30–8.

[75] Hall J, Chawla M, Watson D, Jacob CM, Schoenaker D, Connolly A, et al. Addressing reproductive health needs across the life course: an integrated, community-based model combining contraception and preconception care. The Lancet Public Health. 2023 Jan 1;8(1):e76–84.